A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells.
- Published In:
- MedComm, 7(3), e70630 (2026)
- Authors:
- Park, Jae Hyeon, Lee, Joo Chan, Sharma, Swati(3), Jiang, Chunxue, Lee, Haeun, Park, Hyun-Ju, Kim, Hyung Sik
- Database ID:
- RPEP-15865
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15865APA
Park, Jae Hyeon; Lee, Joo Chan; Sharma, Swati; Jiang, Chunxue; Lee, Haeun; Park, Hyun-Ju; Kim, Hyung Sik. (2026). A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells.. MedComm, 7(3), e70630. https://doi.org/10.1002/mco2.70630
MLA
Park, Jae Hyeon, et al. "A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells.." MedComm, 2026. https://doi.org/10.1002/mco2.70630
RethinkPeptides
RethinkPeptides Research Database. "A Novel Peptide, HS1002, Enhances Antitumor Activity via Dua..." RPEP-15865. Retrieved from https://rethinkpeptides.com/research/park-2026-a-novel-peptide-hs1002
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.